23
https://pubmed.ncbi.nlm.nih.gov/38091841
Astragaloside IV alleviates lipopolysaccharide-induced cardiomyocyte hypertrophy and fibrosis through CCL2-mediated inhibition of the NF-κB signaling pathway, providing a scientific basis for its potential in heart failure treatment.